Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
US-2021269407-A1 · Sep 2, 2021 · US
Synthesis of nirogacestat
US12110277B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12110277-B2 |
| Application number | US-202217929153-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2022 |
| Priority date | Sep 1, 2021 |
| Publication date | Oct 8, 2024 |
| Grant date | Oct 8, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.6% to 0.01% of Compound 2 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 2. The composition of claim 1 , wherein the nirogacestat, or a pharmaceutically acceptable salt thereof, is present in an amount of about 1 mg to about 200 mg. 3. The composition of claim 1 , wherein the nirogacestat, or a pharmaceutically acceptable salt thereof, is present in an amount of about 1 mg to about 150 mg. 4. The composition of claim 1 , wherein the nirogacestat, or a pharmaceutically acceptable salt thereof, is present in an amount of about 1 mg to about 100 mg. 5. The composition of claim 1 , wherein the nirogacestat, or a pharmaceutically acceptable salt thereof, is present in an amount of about 1 mg to about 75 mg. 6. The composition of claim 1 , wherein the nirogacestat, or a pharmaceutically acceptable salt thereof, is present in an amount of about 10 mg to about 60 mg. 7. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.3% to 0.01% of Compound 3 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 8. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.5% to 0.01% of Compound 4 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 9. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.5% to 0.01% of Compound 5 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 10. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.5% to 0.01% of Compound 6 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 11. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.5% to 0.01% of Compound 7 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 12. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.5% to 0.01% of Compound 8 or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13 13. A pharmaceutical composition comprising: (1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and (2) 0.05% to 0.005% of imidazole, or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of Compound 13
Assignees
Inventors
Classifications
- C07D263/44Primary
Two oxygen atoms · CPC title
from compounds containing carboxyl groups by reaction with HCN, or a salt thereof, and amines, or from aminonitriles · CPC title
the other ring being six-membered, e.g. tetraline · CPC title
Optical isomers · CPC title
Imidazole-alkylamines, e.g. histamine, phentolamine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12110277B2 cover?
- The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (“nirogacestat”).
- Who is the assignee on this patent?
- Springworks Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D263/44. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).